NasdaqGS:IONSBiotechs
How Investors Are Reacting To Ionis Pharmaceuticals (IONS) Raising Revenue Guidance and Narrowing Losses
Ionis Pharmaceuticals reported third-quarter 2025 results, with revenue rising to US$156.72 million and net loss narrowing to US$128.61 million compared to the prior year; the company also raised its full-year revenue guidance to a range of US$875 million to US$900 million, above previous expectations.
Management signaled increased investment in commercial preparations for upcoming therapies, highlighting confidence in the company's late-stage pipeline and anticipated product launches next...